Abstract

Type 1 diabetes mellitus was characterized by absolute insulin deficiency requiring lifelong exogenous insulin 
replacement. Traditional insulin delivery methods, including multiple daily injections and conventional insulin 
pumps, impose substantial burdens on patients and often fail to achieve optimal glycemic control. Closed-loop insulin 
delivery systems, also known as artificial pancreas systems, represented a transformative technological advancement 
that automates insulin dosing through real-time continuous glucose monitoring feedback and algorithmic control. 
This review aimed to critically evaluate the technological evolution of closed-loop insulin delivery systems, assess 
their clinical efficacy and safety outcomes in type 1 diabetes management, and examine the biochemical and 
physiological principles underlying their operation. A comprehensive synthesis of peer-reviewed literature 
examining closed-loop system technology, control algorithms, clinical trial outcomes, and real-world 
implementation studies was conducted. Closed-loop systems demonstrated superior glycemic control compared to 
conventional therapy, with increased time in the target glucose range, reduced hypoglycemia frequency, and 
improved glycemic variability metrics. Hybrid closed-loop systems, which retain user input for mealtime boluses, 
have achieved widespread clinical adoption with robust safety profiles. Advanced control algorithms incorporating 
machine learning, adaptive insulin dosing, and predictive capabilities show promise for fully automated systems. 
However, challenges persisted regarding sensor accuracy, algorithm optimization for diverse physiological 
conditions, and equitable access to technology. Closed-loop insulin delivery systems represented a significant 
advancement in type 1 diabetes management, offering improved outcomes through automated glycemic regulation. 
Continued technological refinement and expanded accessibility remain essential priorities.